Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Intangibles (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Intangibles for 5 consecutive years, with $5.3 million as the latest value for Q4 2025.

  • Quarterly Intangibles fell 14.16% to $5.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Dec 2025, down 14.16% year-over-year, with the annual reading at $5.3 million for FY2025, 14.16% down from the prior year.
  • Intangibles for Q4 2025 was $5.3 million at Rhythm Pharmaceuticals, down from $5.5 million in the prior quarter.
  • The five-year high for Intangibles was $8.5 million in Q1 2022, with the low at $4.7 million in Q4 2021.
  • Average Intangibles over 5 years is $6.5 million, with a median of $6.5 million recorded in 2024.
  • The sharpest move saw Intangibles soared 70.54% in 2022, then dropped 14.16% in 2025.
  • Over 5 years, Intangibles stood at $4.7 million in 2021, then soared by 69.24% to $7.9 million in 2022, then dropped by 10.85% to $7.0 million in 2023, then decreased by 12.15% to $6.2 million in 2024, then fell by 14.16% to $5.3 million in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $5.3 million, $5.5 million, and $5.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.